OBJECTIVES: Currently, 23 thousand people (registered) are suffering from Hepatitis C in Germany (more 60% genotype 1). TThe licensing of direct-acting antivirals heralds a new era in the treatment of hepatitis C virus (HCV) genotype 1. Clinical studies showed a significant increase in sustained virological response rates from 38-46% to 63-79%. This study was to evaluate the cost-effectiveness of newly introduced triple therapy with Telaprevir (TVR+PR) compared to dual therapy (PR) for the treatment of genotype 1 hepatitis C virus (HCV) infection in previously untreated patients. METHODS: A systematic literature review identified relevant studies. A Bayesian mixed treatment comparison model was fitted for each patient population. Previously published economic Markov model comparing triple therapy (TVR + PR) and dual therapy (PR) has been adjusted for the Kazakhstan context of health care (payer perspective). Clinical outcomes and dose were taken from the phase ADVANCE-3 trial. Other parameters of the model - including utilities - were adapted from Kazakhstan or if not available from the international literature after an extensive search of the literature. Drug costs were taken from the list of drugs Kazakhstan. All costs were inflated to 2012 goda.Skidka of 3% and the horizon of life were considered. RESULTS: Base-case analysis shows  that the triple treatment (TVR + PR) than dual therapy (PR) leads to increased costs, and the best results. The results were robust when analyzing multiple sensitivity. The discount rate seemed to have a great impact. CONCLUSIONS: Telaprevir triple therapy for previously treated patients with HCV-genotype 1, more efficient than the dual therapy, but it leads to increased costs (in particular, the cost of medications).